By Michael Dabaie
Moderna Inc. shares were up 5% to $342.35 in afternoon trading after the company said it had positive interim data from the Phase 2/3 study of its Covid-19 vaccine candidate in children age six to 11.
The interim analysis showed a robust neutralizing antibody response after two doses of mRNA-1273 at the 50 microgram dose level with a favorable safety profile, the company said Monday.
Moderna plans to submit the data to the Food and Drug Administration, European Medicines Agency and other global regulators in the near term.
The Moderna positive follows Pfizer recently saying it is seeking emergency use authorization for its vaccine in children.
Pfizer Inc. in early October said it and BioNTech officially submitted a request to the FDA for emergency use authorization of their Covid-19 vaccine in children ages five to 11.
Pfizer and BioNTech in late September unveiled results from a Phase 2/3 trial showing a favorable safety profile and robust neutralizing antibody responses in children five to 11 years of age using a two-dose regimen administered 21 days apart, with a smaller dose than that used for people 12 and older.
Pfizer in September said results in children under five years of age are expected as soon as later this year.
Write to Michael Dabaie at firstname.lastname@example.org
(END) Dow Jones Newswires